Novo Nordisk's Narrowed Guidance Suggests Consensus Sales Downgrades -- Market Talk

Dow Jones

Nov 05

0924 GMT - Novo Nordisk's narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

November 05, 2025 04:24 ET (09:24 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2581674233"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581674233\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581674233?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581674233","market":"sh","top_or_hot":-1,"title":"Novo Nordisk's Narrowed Guidance Suggests Consensus Sales Downgrades -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0924 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 04:24 ET (09:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Narrowed Guidance Suggests Consensus Sales Downgrades -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Narrowed Guidance Suggests Consensus Sales Downgrades -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-05 17:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0924 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 04:24 ET (09:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581674233","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581674233","pubTimestamp":1762334640,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0924 GMT - Novo Nordisk's narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德缩小的指引表明普遍销售评级下调——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5},"content_text":"0924 GMT - Novo Nordisk's narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 04:24 ET (09:24 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}